Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

EULAR & ACR Define Rheumatic & Musculoskeletal Disease for Laymen

Thomas R. Collins  |  Issue: July 2018  |  July 19, 2018

nchlsft / shutterstock.com

nchlsft / shutterstock.com

Understanding rheumatic and musculoskeletal diseases (RMDs) is an understandably tall order for the lay public, what with the huge number of conditions and the complex—and often little understood—processes involved.

Now, a working group of the European League Against Rheumatism (EULAR) and the ACR has set out to try to correct this problem with a definition of RMDs in easy-to-understand language. The definition is part of a paper, recently published in Arthritis & Rheumatology and simultaneously in the Annals of Rheumatic Diseases, that also provides a clear and concise synopsis of several important points regarding RMDs that the group feels are important for the public and policymakers to grasp: the diversity of RMDs, their varied pathophysiological pathways, the major burden they pose to individuals and society, and workforce issues regarding care of patients with RMDs.1,2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In general, it is difficult to understand what rheumatic diseases are,” says Desiree van der Heijde, MD, PhD, the paper’s lead author and professor of rheumatology at Leiden University Medical Center in The Netherlands. “It is a heterogeneous group of diseases with different causes, varying outcomes and affecting people at all ages. It is important to understand what rheumatic diseases are [because] they are prevalent and lead to a major burden for both patients and society.”

The group included leaders from EULAR and the ACR, with practicing and academic rheumatologists, a patient representative and a rheumatology health professional.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The goal of this effort was to create a succinct general statement describing RMDs in adults and children in language that can be used in conversations with the general population with and without RMDs; media; healthcare providers; policymakers at local, national and international levels; health insurance companies; charities; employers; and other stakeholders,” the group wrote.

The group crafted this definition:

Rheumatic and musculoskeletal diseases (RMDs) are a diverse group of diseases that commonly affect the joints, but can affect any organ of the body. There are more than 200 different RMDs, affecting both children and adults. They are usually caused by problems of the immune system, inflammation, infections, or gradual deterioration of joints, muscles, and bones. Many of these diseases are long term and worsen over time. They are typically painful and limit function. In severe cases, RMDs can result in significant disability, having a major impact on both quality of life and life expectancy.

Dr. van der Heijde says that although the language and information in the paper will be helpful for communicating with a wide array of people, the most urgent need for improvement is “most likely” in communicating with policymakers.

Page: 1 2 3 | Single Page
Share: 

Filed under:Professional Topics Tagged with:Media

Related Articles

    Désirée Van Der Heijde, MD, PhD, a Key Driver of Treatment Advances

    May 8, 2012

    Dr. van der Heijde learned early in her career that serendipity often plays a role in clinical research and treatment advances.

    “A Common Language for Spondyloarthritis”

    December 1, 2010

    ASAS fills a niche, changes dogma with consensus approach

    ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease

    December 1, 2012

    More finely tuned view of ankylosing spondylitis leads to better treatment, expert says

    To Measure is to Know

    October 1, 2007

    Piet van Riel, MD, PhD, shepherd of RA improvement criteria

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences